Adcendo
At Adcendo, we are developing a new generation of antibody-drug conjugates (ADCs) engineered to address cancers with high unmet medical need.
$75M Series B+ ·
Source: fundraisingfox.com
Funding history ↓Signals
Website registeredJul 22, 2018 (8 years old)
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | $75M | — | fundraisingfox.com |
Timeline
- Website created
Companies like Adcendo
OOna Therapeutics$86.6M Series B+ · Oct 2026
TTubulis$360M Series B+ · Oct 2025PPhrontline Biopharma$40M Series A · Nov 2026
PPanTargPre Seed · Sep 2026
VVelosbioSeries B+ · Aug 2026
AAdcytherixSeries A · Oct 2025
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/adcendo (get a free API key).